Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

l minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay of the webcast will be archived on the Sunesis website for two weeks until March 25, 2008.

About Sunesis' Oncology Programs

Sunesis has built a portfolio of product candidates in oncology focused on inhibition of the cell-cycle and survival signaling. Our lead product candidate, SNS-595, is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 is a specific DNA intercalator and topoisomerase II poison, causing replication-dependent site-selective double-strand DNA damage, irreversible G2 arrest and rapid apoptosis. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 combination with cytarabine in relapsed/refractory AML are both ongoing. SNS-032, a potent and selective inhibitor of CDKs 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory CLL or multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other protein kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information o
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... NEW YORK , Sept. 1, 2015 ... cause of cancer death in American men. ... prostate cancer and 233,000 new cases are diagnosed ... Mount experts are using a powerful new ... both small and large cancer lesions, treating only ...
(Date:9/1/2015)... ... September 01, 2015 , ... VetStem ... , Equine cervical facet joint problems can be caused by injuries and abnormalities ... impingement of nerve roots or of the spinal cord itself. This can manifest ...
(Date:9/1/2015)... Sept. 1, 2015   Medfusion, Inc., ... relationship between doctors and patients, today announced a ... N.C. -based venture capital firms.   ... association with Bull City Venture Partners and Hatteras ... Founder and Executive Chairman. "Both firms, experience working ...
(Date:9/1/2015)... ... September 01, 2015 , ... GenoCAD, a ... groundbreaking new version of its flagship DNA design platform, which has been enhanced ... sequences into numerous genetic parts, which in turn can be recombined using specific ...
Breaking Biology Technology:September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2
... new product pipeline provide positive outlook , ,CHIPPEWA ... lay off workers at its Chippewa Falls plant in ... a recorded a significant increased order backlog of $126 ... and up from $75 million in the previous quarter. ...
... is a good metaphor for the apparently holey (as in Swiss ... to get life science companies off the ground. , ,This ... so the tapestry doesnt fall apart. Last weeks column evoked responses ... mentioning other seed and early stage life science VCs or angel ...
... innovators, would regulators have anything to do? , ,Four ... reminder that for every breakthrough in fields such as ... slow the sprint toward progress. , ,That wouldnt be ... based on scientific inquiry, but sometimes the barriers are ...
Cached Biology Technology:Cray reports $54.5 million loss, plans layoff in Chippewa Falls 2Cray reports $54.5 million loss, plans layoff in Chippewa Falls 3More Midwest Seed-Stage Life Science VCs 2More Midwest Seed-Stage Life Science VCs 3More Midwest Seed-Stage Life Science VCs 4More Midwest Seed-Stage Life Science VCs 5More Midwest Seed-Stage Life Science VCs 6Technology regulation spurred by a mix of science and politics 2Technology regulation spurred by a mix of science and politics 3
(Date:8/10/2015)... August 10, 2015 The latest 364 ... comprehensive analysis of the global border security market . ... of $16.4bn in 2015. Now: Border security is ... example of the business critical issue you need to know ... visiongain ,s objective analysis of how this will impact your ...
(Date:8/5/2015)... 5, 2015 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... facial recognition is forecast to reach US$ 2,671.8 Mn ... for surveillance systems by civil and government agencies. This ... and terrorist activities across the globe that would elevate ...
(Date:7/31/2015)... juli 2015 Den 10. internationale konference om ... den 22. - 25. oktober i Shenzhen ... 10-års fødselsdag i år. Siden starten i 2006 er ... på ,omik,-feltet, og er en af de mest dynamiske, ... fokuserer på nylige gennembrud og fremskridt inden for ,omik,-forskning, ...
Breaking Biology News(10 mins):Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... which finally proves that bones found in Shropshire, England ... in North Western Europe publishes today in the ... the surrounding environment suggests that some mammoths remained part ... to have become extinct. The mammoth bones, consisting ...
... dinosaur in China. The finding, they say, demonstrates that ... the Jurassic period than previously thought, and offers important ... from the hand of dinosaurs. The discovery is ... of the journal Nature . "This work ...
... of researchers, which includes scientists at the Virginia Bioinformatics ... sequence of Azotobacter vinelandii , uncovering important genetic ... of the biology of this versatile, soil-living bacterium. The ... ,s role as a model study organism for investigation ...
Cached Biology News:New discovery suggests mammoths survived in Britain until 14,000 years ago 2Beaked, bird-like dinosaur tells story of finger evolution 2Scientists sequence genome of the N2-fixing, soil-living bacterium Azotobacter vinelandii 2Scientists sequence genome of the N2-fixing, soil-living bacterium Azotobacter vinelandii 3
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
... GenBank Accession Number : NM_201222 ... corresponding to amino acids 161-176 ... antiserum in 0.05% sodium azide ... routinely evaluated by immunoblot on ...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Immunofixation Gel Kit, requires IF100 Reactivity: Human Applications: Immunofixation ...
Biology Products: